Novavax Allows Participants On Placebo Arm To Get COVID-19 Vaccine In Trials

Comments
Loading...
  • Novavax Inc NVAX said that participants in its ongoing COVID-19 vaccine trials in South Africa and the U.K. could receive additional shots, ensuring those who received a placebo can also get the active vaccine.
  • Allowing volunteers to crossover to the active vaccine will enable participants to continue in trials and remain blinded.
  • The company said it planned to cross over participants in its ongoing large, late-stage study in the U.S. and Mexico. The company plans to read out initial clinical data during the second quarter.
  • As part of the updated trial protocol, all participants in the U.K. and the U.S. will be offered the chance to receive an additional round of shots, the company said.
  • Participants who opt to do so will receive two additional doses of either vaccine for those who initially received placebo or placebo for those who first got the vaccine.
  • Price Action: NVAX shares are trading 4.2% lower at $178 in the premarket session on the last check Tuesday.
NVAX Logo
NVAXNovavax Inc
$7.99-2.20%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum83.98
Growth86.11
Quality-
Value26.51
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In: